NOT-CA-18-061: Notice of NCI's participation on PAR-18-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)

Notice of NCI's participation on PAR-18-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)

Notice Number: NOT-CA-18-061

Key Dates
Release Date: April 2, 2018

Related Announcements
PAR-18-064

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating in PAR-18-064, "Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)." The following changes have been made to reflect NCI's participation in this FOA:

Part 1. Overview Information
Components of Participating Organizations
National Institute on Drug Abuse (NIDA)
National Cancer Institute (NCI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)
93.279, 93.399

Part 2. Full Text of Announcement
Section I. Funding Opportunity Description The text that follows this sentence is hereby to be considered as information inserted just after (below) the bulleted list of examples of appropriate and/or pilot trial studies presented as part of the Research Objectives in the original Funding Opportunity Description in Part 2, Section I, of PAR-18-064.
"In addition to research areas already listed in the Funding Opportunity Description, the National Cancer Institute (NCI) is interested in applications that address an extraordinary opportunity in this area by:

Utilizing natural experiment, observational, or ecological designs to study the population impact of the court-ordered, tobacco-related corrective statements implemented as part of the Department of Justice's racketeering case, "United States v. Philip Morris USA, Inc," which are currently being disseminated on television and in newspapers and soon will be disseminated on tobacco company Web sites, cigarette pack onserts, and possibly at point-of-sale."

In Section VII. Agency Contacts, the following contacts have been added to the FOA.

Under Scientific/Research Contact(s):
Kelly D. Blake, Sc.D.
National Cancer Institute (NCI)
Telephone: 240-281-5934
Email: [email protected]

Under Financial/Grants Management Contact(s):
Carol Perry
National Cancer Institute (NCI)
Telephone: 240-281-6282
Email: [email protected]

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Kelly D. Blake, Sc.D.
National Cancer Institute
Telephone: 240-281-5934
Email: [email protected]